Sirtuin 1 is a protein deacetylase that regulates a large number of proteins often
functionally implicated in tumor development and progression. Its pleiotropic function has turned
SIRT1 into an attractive chemotherapeutic target, underscored by very promising preclinical results
with SIRT1 inhibitors in the treatment of chronic myeloid leukemia. Here, we revisit the studies on
SIRT1 as an emerging target for therapy in pancreatic cancer, a tumor with dismal outcomes for
which currently few therapeutic options are available. We highlight those potential SIRT1 target
genes that are commonly affected in pancreatic cancer according to recent genomic analyses.
Keywords: Chemotherapy, Deleted in breast cancer 1, genomic, mutation, pancreas, personalized medicine, Sirtuin 1.
Rights & PermissionsPrintExport